GE HealthCare Technologies (GEHC) Launches New Ultrasound Systems, Is The Stock Still A Bargain?
GE HealthCare Technologies (GEHC) has rolled out new ultrasound products that are drawing fresh attention to the stock. The LOGIQ e laptop systems and expanded breast imaging platform combine AI tools, portability and regulatory clearances.
See our latest analysis for GE HealthCare Technologies.
The LOGIQ e and Invenia ABUS launches come after a strong stretch for GE HealthCare Technologies, with a 30 day share price return of 16.8% and a 90 day share price return of 19.8% lifting the stock to US$73.69. This is even though the year to date share price return is still down 11% and the 1 year total shareholder return is just 0.6%, which points to momentum building only in recent months.
If these ultrasound advances have caught your attention, it can also be a good time to see what other healthcare imaging and AI opportunities are setting up in the market through the 42 healthcare AI stocks.
After a near 20% move in 30 days and fresh ultrasound launches, GE HealthCare Technologies now sets up as a valuation question. Do the current P/E and implied discount still leave more upside for new buyers, or not?
Most Popular Narrative: 9.8% Undervalued
GE HealthCare Technologies closed at $73.69 against a narrative fair value of $81.72, which frames the recent ultrasound launches against a still discounted stock.
The pipeline of new high-impact products, like Radiopharmaceuticals, Total Body PET, and Photon Counting CT, is anticipated to drive future revenue growth and potentially improve margins.
Want to understand why this narrative still sees upside from today’s price? It hinges on measured growth assumptions, margin shifts and a leaner share count. The full story connects those moving parts to a higher long term earnings base and a lower required return baked into the model.
Result: Fair Value of $81.72 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the GE HealthCare Technologies narrative still hinges on tariff exposure and China regulation risks, which could pressure margins and challenge revenue assumptions if conditions worsen.
Find out about the key risks to this GE HealthCare Technologies narrative.
Next Steps
Mixed signals on GE HealthCare Technologies so far. The strongest views highlight both risks and rewards, so you may want to act quickly and shape your own view by checking the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond GE HealthCare Technologies?
If GE HealthCare Technologies has you thinking harder about your portfolio, do not stop here. Use the Simply Wall Street Screener to spot fresh opportunities and avoid getting left behind.
- Target potential mispricings by scanning for companies that look attractively valued using the 52 high quality undervalued stocks.
- Strengthen your income stream by focusing on reliable cash payouts through the 10 dividend fortresses.
- Sleep easier by concentrating on companies with sturdier finances via the 80 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com